Project COMET: Massed Prolonged Exposure for PTSD and SUD
This study, called Project COMET, is looking at a treatment called Massed Prolonged Exposure Therapy (M-PE) for adults who have both Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders (SUD). M-PE is a type of therapy delivered over a shorter time frame, like 10 sessions in 2-4 weeks, compared to weekly sessions. Researchers want to see if M-PE can better reduce PTSD symptoms and substance use compared to standard SUD care. They will also look at other important outcomes like depression, suicidal thoughts, and quality of life. You may be able to join if you are 18 or older, are already in SUD treatment, and meet criteria for both PTSD and SUD. The study is currently unclear on its recruitment status and plans to enroll 168 participants.
- Study design
- This is an interventional study comparing Massed Prolonged Exposure Therapy (M-PE) to standard outpatient SUD care. It plans to enroll 168 participants.
- What's involved
- Participants will receive either Massed Prolonged Exposure Therapy (M-PE) over 2-4 weeks or standard intensive outpatient SUD treatment, which includes resilience groups, peer support, and individual therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months after randomization, with assessments at 6 weeks, 10 weeks, 18 weeks, and 30 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Project COMET: Massed Prolonged Exposure for PTSD and SUD
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sonya Norman Professor Of Clinical, Psychiatry, Ph.D · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Clinician Administered PTSD Scale for DSM-5 (CAPS-5)Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up
Measures PTSD symptom severity, score range 0-80, higher scores mean greater symptom severity
- Time Line Follow back (TLFB)Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up
Measures percent days of alcohol or other drug use, score range 0-100%, higher scores indicate greater percent days of use